Patients taking the antifibrotic medications nintedanib and pirfenidone for idiopathic pulmonary fibrosis had reduced all-cause mortality and hospitalizations for up to 2 years compared with a matched untreated cohort.
In patients with idiopathic pulmonary fibrosis, anorexia and weight loss during prior treatment with pirfenidone was associated with early termination of subsequent nintedanib therapy.
Use of a calcium-based therapeutic approach may be helpful for the management of an atypical form of pulmonary fibrosis.
Investigators sought to determine a potential link between mPA/Ao ratio at diagnosis and clinical characteristics and outcomes in patients with idiopathic pulmonary fibrosis.
Based on the 2016 International Working Group (IWG) diagnostic criteria for idiopathic pulmonary fibrosis (IPF), outcomes are relatively similar between patients with IPF with pneumonia and patients with an acute IPF exacerbation.
A novel treatment for idiopathic pulmonary fibrosis, PRM-151, has been granted Breakthrough Therapy designation by the FDA.
Patients with idiopathic pulmonary fibrosis with better CT indices such as FEV1 and mean lung attenuation had improved outcomes.
Researchers retrospectively analyzed the association among physiologic measurements, survival, and quantitative high-resolution computed tomographic indices in patients with idiopathic pulmonary fibrosis.
Fewer than 25% of patients with idiopathic pulmonary fibrosis who were treated with the antifibrotic drug pirfenidone showed signs of disease progression.
A new clinical practice guidelines summary for clinicians regarding idiopathic pulmonary fibrosis has been released, which describes clinical manifestations and diagnostic interventions for the disease.
